

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |      |                          |                           |
|---|------|--------------------------|---------------------------|
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |      | <b>Complete if Known</b> |                           |
|   |      | Application Number       | 10/529,511                |
|   |      | Filing Date              | §371 of PCT/IL2003/000764 |
|   |      | First Named Inventor     | Hermona Soreq             |
|   |      | Art Unit                 |                           |
|   |      | Examiner Name            |                           |
| Sheet 1   | of 6 | Attorney Docket Number   | 74136/JPW/JW              |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
| RK                              | 1 /                   | Abbott C. A., Mackness, M. I., Kumar, S., Olukoga, O., Gordon, C., Arrol, S., Bhatagar, D., Boulton, A. J. M., and Durrington, P. N. (1993) Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. <i>Clin. Sci. (Lond)</i> 85: 77-81           |                |
|                                 | 2 /                   | Adkins, S., Gan, K.N., Mody, M., and La Du, B. N. (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. <i>Am. J Hum. Genet.</i> 52: 598-608  |                |
|                                 | 3 /                   | Akhmedova, S., Anisimov, S., Yakimovsky, A., and Schwartz, E. (1999) Gln → Arg 191 polymorphism of paraoxonase and Parkinson's disease. <i>Hum. Hered.</i> 49: 178-180  |                |
|                                 | 4                     | Aminoff, M. J. (2001) Parkinson's disease and other extrapyramidal disorders. In: Braunwald, E., et al. (eds) Harrison's principles of internal medicine. McGraw Hill, pp. 2399-2406  |                |
|                                 | 5                     | Bartels, C. F., Jensen, F. S., Lockridge, O., van der Spek, A. F., Rubinstein, H. M., Lubrano, T., and La Du, B. N. (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. <i>Am. J. Hum. Genet.</i> 50: 1086-1103 |                |
|                                 | 6                     | Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000) Chronic-systemic pesticide exposure reproduces features of Parkinson's disease. <i>Nature Neurosci.</i> 3: 1301-1306   |                |
|                                 | 7                     | Brindle, N., Song, Y., Rogaeva, E., Premkumar, S., Levesque, G., Yu, G., Ikeda, M., Nishimura, M., Paterson, A., Sorbi, S., Duara, R., Farrer, L., and St George-Hyslop, P. (1998) Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. <i>Hum. Mol. Genet.</i> 7: 933-935  |                |
|                                 | 8                     | Brophy, V. H., Jampsa, R. L., Clendenning, J. B., McKinsty, L. A., Jarvik, G. P., and Furlong, C. E. (2001) Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. <i>Am. J. Hum. Genet.</i> 68: 1428-1436  |                |
|                                 | 9                     | Brophy, V. H., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, G. P., and Furlong, C. E. (2001) Polymorphisms in the human paraoxonase (PON1) promoter. <i>Pharmacogenetics</i> 11: 77-84  |                |
| ✓                               | 10                    | Burkhardt, C., Kelly, J. P., Lim, Y. H., Filley, C. M., and Parker, W. D. Jr. (1993) Neuroleptic medications inhibit complex I of the electron transport chain. <i>Ann. Neurol.</i> 33: 512-517   |                |

|                    |                      |                 |          |
|--------------------|----------------------|-----------------|----------|
| Examiner Signature | <i>Hermona Soreq</i> | Date Considered | 10/20/06 |
|--------------------|----------------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Hermona Soreq, et al.  
 U.S. Serial No. 10/529,511  
 Filed: as §371 national stage of  
 PCT/IL2003/000764  
 Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |                        |                          |                           |
|---|------------------------|--------------------------|---------------------------|
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |                        | <b>Complete if Known</b> |                           |
|   |                        | Application Number       | 10/529,511                |
|   |                        | Filing Date              | §371 of PCT/IL2003/000764 |
|   |                        | First Named Inventor     | Hermona Soreq             |
|   |                        | Art Unit                 |                           |
|   |                        | Examiner Name            |                           |
| Sheet 2 of 6  | Attorney Docket Number | 74136/JPW/JW             |                           |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
| RK                              | 11                    | Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker, W. D. Jr., and Bennett, J. P. Jr. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. <i>Biochim. Biophys. Acta</i> , 1362: 77-86                     |                |
|                                 | 12                    | Costa, L. G., Cole, T. B., Jarvik, G. P., and Furlong, C. E. (2003) Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. <i>Annu. Rev. Med.</i> 54: 371-392  |                |
|                                 | 13                    | Costa, L. G., Richter, R. J., Murphy, S. D., Omenn, G. S., Motulsky, A. G., and Furlong, C. E. (1987) Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In: Costa, L. G. (eds.) <i>Toxicology of pesticides: experimental, clinical and regulatory perspectives</i> . Springer-Verlag, Heidelberg, pp. 263-266 |                |
|                                 | 14                    | Costa, L. G., Li, W. F., Richter, R. J., Shih, D. M., Lusis, A., and Furlong, C. E. (1999) The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. <i>Chem. Biol. Interact.</i> 119-120: 429-438  |                |
|                                 | 15                    | Dempster, A. P., Laird, N. M., and Rubin, D. B. (1977) Maximum Likelihood from Incomplete Data via the EM Algorithm. <i>J. Royal Statist. Soc. Ser. B.</i> 39  |                |
|                                 | 16                    | Furlong, C. E., Li, W. F., Costa, L. G., Richter, R. J., Shih, D. M., and Lusis, A. J. (1998) Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. <i>Neurotoxicology</i> 19: 645-650  |                |
|                                 | 17                    | Goldsmith, J. R., Herishanu, Y., Abarbanel, J. M., and Weinbaum, Z. (1990) Clustering of Parkinson's Disease Points to Environmental Etiology. <i>Arch. Environ. Health</i> 45: 88-94  |                |
|                                 | 18                    | Haley, R. W., Billecke, S., and La Du, B. N. (1999) Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. <i>Toxicol. Appl. Pharmacol.</i> 157: 227-233  |                |
|                                 | 19                    | Herishanu, Y. O., Goldsmith, J. R., Abarbanel, J. M., and Weinbaum, Z. (1989) Clustering of Parkinson's Disease in Southern Israel. <i>Can. J. Neurol. Sci.</i> 16: 402-405  |                |
| ✓                               | 20                    | Hodgson, E. and Lewy, P. E. (1996) Pesticides: An Important but Underused Model for the Environmental Health Sciences. <i>Environ. Health Perspect.</i> 104: 97-106  |                |

|                    |                    |                 |          |
|--------------------|--------------------|-----------------|----------|
| Examiner Signature | <i>Kerame Koon</i> | Date Considered | 10/20/06 |
|--------------------|--------------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

|   |                        |                          |                            |
|---|------------------------|--------------------------|----------------------------|
| Substitute for form 1449/PTO  |                        | <b>Complete If Known</b> |                            |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |                        | Application Number       | 10/529,511                 |
|   |                        | Filing Date              | \$371 of PCT/IL2003/000764 |
|   |                        | First Named Inventor     | Hermona Soreq              |
|   |                        | Art Unit                 |                            |
|   |                        | Examiner Name            |                            |
| Sheet 3 of 6  | Attorney Docket Number | 74136/JPW/JW             |                            |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
| RK                              | 21                    | Jenner, P. and Olanow, C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. <i>Neurology</i> 47(Suppl 3): S161-S170  |                |
|                                 | 22                    | Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998) Mutation in the parkin gene cause autosomal recessive juvenile parkinsonism. <i>Nature</i> 392: 605-608  |                |
|                                 | 23                    | Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding $\alpha$ -synuclein in Parkinson's disease. <i>Nat. Genet.</i> 18: 106-108  |                |
|                                 | 24                    | Lang, A. E. and Lozano, A. M. (1998) Parkinson's Disease. First of Two Parts. <i>N. Engl. J. Med.</i> 339: 1044-1053   |                |
|                                 | 25                    | Le Couteur, D. G., Muller, M., Yang, M. C., Mellick, G. D., and McLean, A. J. (2002) Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. <i>Rev. Environ. Health</i> 17: 51-64   |                |
|                                 | 26                    | Lehmann, D. J., Nagy, Z., Litchfield, S., Borja, M. C., and Smith, A. D. (2000) Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. <i>Hum. Genet.</i> 106: 447-452   |                |
|                                 | 27                    | Lehmann, D. J., Johnston, C., and Smith, A. D. (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. <i>Hum. Mol. Genet.</i> 6: 1933-1936  |                |
|                                 | 28                    | Lockridge, O. and Masson, P. (2000) Pesticides and Susceptible Populations: People With Butyrylcholinesterase Genetic Variants May Be At Risk. <i>Genetic Neurotoxicology</i> 21: 113-126  |                |
|                                 | 29                    | Loewenstein-Lichtenstein, Y., Schwarz, M., Glick, D., Norgaard-Pedersen, B., Zakut, H., and Soreq, H. (1995) Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers. <i>Nat. Med.</i> 1: 1225-1226   |                |
|                                 | 30                    | Lucking, C. B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Deneffe, P., Wood, N. W., Agid, Y., and Brice, A. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. <i>N. Engl. J. Med.</i> 342: 1560-1567 |                |

|                    |                      |                 |          |
|--------------------|----------------------|-----------------|----------|
| Examiner Signature | <i>Koranne Kozov</i> | Date Considered | 10/20/06 |
|--------------------|----------------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                           |
|---|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p> |   | <b>Complete if Known</b> |                           |
|   |   | Application Number       | 10/529,511                |
|   |   | Filing Date              | §371 of PCT/IL2003/000764 |
|   |   | First Named Inventor     | Hermona Soreq             |
|   |   | Art Unit                 |                           |
|   |   | Examiner Name            |                           |
| Sheet   | 4 | of                       | 6                         |
|   |   | Attorney Docket Number   | 74136/JPW/JW              |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
| RK                              | 31                    | Mackness, B., Durrington, P. N., and Mackness, M. I. (1998) Human Serum Paraoxonase. <i>Gen. Pharmacol.</i> 31: 329-336   |                |
|                                 | 32                    | Masson, P., Josse, D., Lockridge, O., Viguie, N., Taupin, C., and Buhler, C. (1998) Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. <i>J. Physiol. (Paris)</i> 92: 357-362  |                |
|                                 | 33                    | Menegon, A., Board, P. G., Blackburn, A. C., Mellick, G. D., and Le Couteur, D. G. (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. <i>Lancet</i> 352: 1344-1346  |                |
|                                 | 34                    | Nassar, B. A., Dunn, J., Title, L. M., O'Neill, B. J., Kirkland, S. A., Zayed, E., Bata, I. R., Cantrill, R. C., Johnstone, J., Dempsey, G. I., Tan, M. H., Breckenridge, W. C., and Johnstone, D. E. (1999) Relation of genetic polymorphisms of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100, and glycoprotein IIIa and early-onset coronary heart disease. <i>Clin. Biochem.</i> 32: 275-282                    |                |
|                                 | 35                    | Nassar, B. A., Darvesh, S., Bevin, L. D., Rockwood, K., Kirkland, S. A., O'Neill, B. J., Bata, I. R., Johnstone, D. E., and Title, L. M. (2002) Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E ε4 genes in early-onset coronary artery disease. <i>Clin. Biochem.</i> 5: 205-209   |                |
|                                 | 36                    | Parker, W. D. and Swerdlow, R. H. (1998) Mitochondrial dysfunction in idiopathic Parkinson disease. <i>Am. J. Hum. Genet.</i> 62: 758-762   |                |
|                                 | 37                    | Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. <i>Science</i> 276: 2045-2047 |                |
|                                 | 38                    | Premkumar, D. R., Cohen, D. L., Hedera, P., Friedland, R. P., and Kalaria, R. N. (1996) Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. <i>Am. J. Pathol.</i> 148: 2083-2095  |                |
|                                 | 39                    | Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α-Synuclein in Lewy Bodies. <i>Nature</i> 388: 839-40  |                |
| ↓                               | 40                    | Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., Shindo, M., Tanaka, H., and Hashimoto, K. (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. <i>Atherosclerosis</i> 150: 295-298   |                |

|                    |                     |                 |          |
|--------------------|---------------------|-----------------|----------|
| Examiner Signature | <i>Koranne Kozm</i> | Date Considered | 10/20/06 |
|--------------------|---------------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

|                        |  |                            |
|------------------------|--|----------------------------|
| Application Number     |  | 10/529,511                 |
| Filing Date            |  | \$371 of PCT/IL2003/000764 |
| First Named Inventor   |  | Hermona Soreq              |
| Art Unit               |  |                            |
| Examiner Name          |  |                            |
| Attorney Docket Number |  | 74136/JPW/JW               |

Sheet

5

of

6

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.    | T <sup>2</sup> |
|--------------------|-----------------------|--|----------------|
| RVL                | 41                    | Sveinbjörnsdóttir, S., Hicks, A. A., Jónsson, T., Pétursson, H., Guðmundsson, G., Grigge, M. L., Kong, A., Gulcher, J. R., and Stefánsson, K. (2000) Familial Aggregation of Parkinson's Disease in Iceland. <i>N. Engl. J. Med.</i> 343: 1765-1770                |                |
|                    | 42                    | Tanner, C. M., Ottman, R., Ellenberg, J. H., Goldman, S. M., Mayeux, R., Chan, P., and Langston, J. W. (1997) Parkinson's Disease (PD) Concordance in Elderly Male Monozygotic (MZ) and Dizygotic (DZ) Twins. <i>Neurology</i> 48(Suppl): A333                     |                |
|                    | 43                    | Taylor, M. C., Le Couteur, D. G., Mellick, G. D., and Board, P. G. (2000) Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. <i>J. Neural Transm.</i> 107: 979-983   |                |
|                    | 44                    | Vays, I., Heikkila, R. E., and Nicklas, W. J. (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. <i>J. Neurochem.</i> 46: 1501-1507 |                |
|                    | 45                    | Vingerhoets, F. J. G., Snow, B. J., Tetud, J. W., Langston, J. W., Schulzer, M., and Calne, D. B. (1994) Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. <i>Ann. Neurol.</i> 36: 765-770                        |                |
|                    | 46                    | Wang, J. and Liu, Z. (2000) No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. <i>Mov. Disord.</i> 15: 1265-1267  |                |
|                    | 47                    | Wooten, G. F., Currie, L. J., Bennett, J. P., Harrison, M. B., Trugman, J. M., and Parker, W. D. Jr. (1997) Maternal inheritance in Parkinson's disease. <i>Ann. Neurol.</i> 41: 265-268   |                |
|                    | 48                    | Poewe, W. H. and Wenning, G. K. (1996) The natural history of Parkinson's disease. <i>Neurology</i> 47(Suppl 3): S146-S152   |                |
|                    | 49                    | International Preliminary Examination Report issued by the International Preliminary Examination Authority (IPEA/EP) on December 27, 2004 in connection with International Application No. PCT/IL2003/000764   |                |
|                    | 50                    | International Search Report issued by the International Searching Authority (ISA/EP) on April 6, 2004 in connection with International Application No. PCT/IL2003/000764   |                |

Examiner  
Signature

*Cheranne Korman*

Date

Considered

10/20/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

|   |                        |                          |                           |
|---|------------------------|--------------------------|---------------------------|
| Substitute for form 1449/PTO  |                        | <b>Complete if Known</b> |                           |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |                        | Application Number       | 10/529,511                |
|   |                        | Filing Date              | §371 of PCT/IL2003/000764 |
|   |                        | First Named Inventor     | Hermona Soreq             |
|   |                        | Art Unit                 |                           |
|   |                        | Examiner Name            |                           |
| Sheet 6 of 6  | Attorney Docket Number | 74136/JPW/JW             |                           |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                    | T <sup>2</sup> |
| PK                              | 51                    | Akhmedova, S. N., Yakimovsky, A. K., and Schwartz, E. I. (2001) Paraoxonase I Met-Leu 54 Polymorphism Is Associated With Parkinson's Disease. <i>J. Neurol. Sci.</i> 184: 179-182  |                |
|                                 | 52                    | Shapira, M., Tur-Kaspa, I., Bosgraaf, L., Livni, N., Grant, A. D., Grisaru, D., Komer, M., Ebstein, R. P., and Soreq, H. (2000) A transcription-activating polymorphism in the AChE promoter associated with acute sensitivity to anti-acetylcholinesterases. <i>Hum. Mol. Genet.</i> 9: 1273-1281 |                |
|                                 | 53                    | Kondo, I. and Yamamoto, M. (1998) Genetic Polymorphism Of Paraoxonase I (PON1) And Susceptibility To Parkinson's Disease. <i>Brain Res.</i> , 806: 271-273   |                |
|                                 | 54                    | Bartels, C. F., Zelinski, T., and Lockridge, O. (1993) Mutation at Codon 322 in the Human Acetylcholinesterase (ACHE) Gene Accounts for YT Blood Group Polymorphism. <i>Amer. J. Hum. Genet.</i> 52: 928-936   |                |
|                                 | 55                    | Carmine, A., Buervenich, S., Sydow, O., Anvret, M., and Olson, L. (2002) Further Evidence for an Association of the Paraoxonase I (PON1) Met-54 Allele with Parkinson's Disease. <i>Movement Disord.</i> 17: 764-766   |                |
|                                 | 56                    | Kaufer, D. and Soreq, H. (1999) Tracking Cholinergic Pathways from Psychological and Chemical Stressors to Variable Neurodeterioration Paradigms. <i>Curr. Opin. Neurol.</i> 12: 739-743   |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |

|                    |                       |                 |          |
|--------------------|-----------------------|-----------------|----------|
| Examiner Signature | <i>Rosanne Kassar</i> | Date Considered | 10/20/06 |
|--------------------|-----------------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.